RU2014130022A - Ингибиторы сиалоадгезина для лечения заболеваний, вызванных вирусами, имеющими оболочку - Google Patents

Ингибиторы сиалоадгезина для лечения заболеваний, вызванных вирусами, имеющими оболочку Download PDF

Info

Publication number
RU2014130022A
RU2014130022A RU2014130022A RU2014130022A RU2014130022A RU 2014130022 A RU2014130022 A RU 2014130022A RU 2014130022 A RU2014130022 A RU 2014130022A RU 2014130022 A RU2014130022 A RU 2014130022A RU 2014130022 A RU2014130022 A RU 2014130022A
Authority
RU
Russia
Prior art keywords
sialyllactose
antigen
molecule
sialoadhesin
hiv
Prior art date
Application number
RU2014130022A
Other languages
English (en)
Russian (ru)
Inventor
УСЕРОС Нурия ИСКЬЕРДО
Ханс-Георг Краусслих
Майэр ЛОРИСАТЕ
ПИКАДО Хавьер МАРТИНЕС
Original Assignee
Лабораторьос Дель Др. Эстеве, С.А.
Фундасио Привада Институт Де Ресерка Де Ля Сида-Кайкса
Институсио Каталана Де Ресерка И Эстудис Аванкатс
Рупрехт-Карлс-Универзитет Хайдельберг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лабораторьос Дель Др. Эстеве, С.А., Фундасио Привада Институт Де Ресерка Де Ля Сида-Кайкса, Институсио Каталана Де Ресерка И Эстудис Аванкатс, Рупрехт-Карлс-Универзитет Хайдельберг filed Critical Лабораторьос Дель Др. Эстеве, С.А.
Publication of RU2014130022A publication Critical patent/RU2014130022A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
RU2014130022A 2011-12-22 2012-12-17 Ингибиторы сиалоадгезина для лечения заболеваний, вызванных вирусами, имеющими оболочку RU2014130022A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161579242P 2011-12-22 2011-12-22
EP11382392.6 2011-12-22
US61/579,242 2011-12-22
EP11382392.6A EP2606897A1 (en) 2011-12-22 2011-12-22 Methods and compositions for the treatment of diseases caused by enveloped viruses
PCT/EP2012/075831 WO2013092509A1 (en) 2011-12-22 2012-12-17 Inhibitors of sialoadhesin for the treatment of diseases caused by enveloped viruses

Publications (1)

Publication Number Publication Date
RU2014130022A true RU2014130022A (ru) 2016-02-10

Family

ID=45445920

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014130022A RU2014130022A (ru) 2011-12-22 2012-12-17 Ингибиторы сиалоадгезина для лечения заболеваний, вызванных вирусами, имеющими оболочку

Country Status (14)

Country Link
US (1) US9789130B2 (cg-RX-API-DMAC7.html)
EP (2) EP2606897A1 (cg-RX-API-DMAC7.html)
JP (1) JP6143781B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140130664A (cg-RX-API-DMAC7.html)
CN (1) CN104168903B (cg-RX-API-DMAC7.html)
AU (1) AU2012357968B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014015112A2 (cg-RX-API-DMAC7.html)
CA (1) CA2858499A1 (cg-RX-API-DMAC7.html)
HK (1) HK1202820A1 (cg-RX-API-DMAC7.html)
IL (1) IL233207A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014007605A (cg-RX-API-DMAC7.html)
RU (1) RU2014130022A (cg-RX-API-DMAC7.html)
WO (1) WO2013092509A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403861B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10004695B2 (en) 2014-04-16 2018-06-26 Trustees Of Boston University GM3 functionalized nanoparticles
CN104587491A (zh) * 2014-12-30 2015-05-06 天津大学 SAMHD1-pLNCX2制备抗肿瘤药物的用途
US20190142761A1 (en) * 2016-05-06 2019-05-16 WRS Nutraceuticals Pty Ltd Agent delivery system
US11249081B2 (en) 2016-08-31 2022-02-15 Agency For Science, Technology And Research Methods for the identification, targeting and isolation of human dendritic cell (DC) precursors “pre-DC” and their uses thereof
CN108165559B (zh) * 2017-11-29 2021-06-18 昆明理工大学 一种c2h2型转录因子基因及其应用
KR20230099676A (ko) * 2021-12-27 2023-07-04 주식회사 진켐 시알릴락토스를 이용한 혈뇌장벽 투과용 약물 전달체
EP4493198A1 (en) * 2022-03-16 2025-01-22 Pharmalectin, Inc. Lectin-binding carbohydrates for treating viral infections
KR20240102304A (ko) * 2022-12-26 2024-07-03 주식회사 진켐 신규한 젬시타빈 결합체 및 이의 용도
CN117886891B (zh) * 2024-03-15 2024-06-07 黑龙江八一农垦大学 靶向巨噬细胞cd169受体的多肽及其应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
US3888975A (en) 1972-12-27 1975-06-10 Alza Corp Erodible intrauterine device
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (cg-RX-API-DMAC7.html) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
NL7807532A (nl) 1978-07-13 1980-01-15 Akzo Nv Metaal-immunotest.
FR2433949A1 (fr) 1978-08-25 1980-03-21 Commissariat Energie Atomique Substrat hydrophobe apte a liberer une substance chimique
US4954487A (en) 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
NL8000173A (nl) 1980-01-11 1981-08-03 Akzo Nv Toepassing van in water dispergeerbare, hydrofobe kleurstoffen als label in immunochemische testen.
US4360013A (en) 1980-04-21 1982-11-23 Minnesota Mining And Manufacturing Company Polymeric acid contraceptive devices
IT1131833B (it) 1980-06-20 1986-06-25 Crinos Industria Farmaco Eccipienti per sostanze spermicide
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4368186A (en) 1981-05-07 1983-01-11 Syntex (U.S.A.) Inc. Methods and compositions for intravaginal contraception
US4415585A (en) 1982-03-11 1983-11-15 University Of Illinois Foundation Contraceptive method
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US5248700A (en) 1982-05-14 1993-09-28 Akzo Nv Active agent containing solid structures for prolonged release of active agents
US4961931A (en) 1982-07-29 1990-10-09 Alza Corporation Method for the management of hyperplasia
US4499154A (en) 1982-09-03 1985-02-12 Howard L. Podell Dipped rubber article
US4551148A (en) 1982-09-07 1985-11-05 Kv Pharmaceutical Company Vaginal delivery systems and their methods of preparation and use
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
JP2754206B2 (ja) * 1987-11-17 1998-05-20 メクト株式会社 α２→３結合を認識するモノクローナル抗体
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
US5624824A (en) 1989-03-24 1997-04-29 Yale University Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
US5208031A (en) 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
US5286634A (en) 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
DE4015543A1 (de) 1990-05-15 1991-11-21 Bayer Ag Spermicides beschichtungsmittel
EP0467078B1 (en) 1990-07-18 1996-05-08 Abbott Laboratories An analyte-subtitute reagent for use in specific binding assay methods, devices and kits
US5143731A (en) 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
FR2666587B1 (fr) 1990-09-10 1993-06-25 Dow Corning Sa Compositions de lubrifiant et leur utilisation.
GB9021061D0 (en) 1990-09-27 1990-11-07 Unilever Plc Encapsulating method and products containing encapsulated material
AU687733B2 (en) 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
IL105503A (en) * 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
US5698411A (en) 1995-05-18 1997-12-16 Coulter Corporation Method for determining activity of enzymes in metabolically active whole cells
US5976822A (en) 1995-05-18 1999-11-02 Coulter International Corp. Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis
US5759781A (en) 1995-12-22 1998-06-02 Yale University Multiparametric fluorescence in situ hybridization
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5876935A (en) 1997-01-08 1999-03-02 Dade Behring Inc. Luminescent specific binding assay
SE9700383D0 (sv) 1997-02-04 1997-02-04 Pharmacia Biotech Ab An adsorption/separation method and a medium for adsorption/separation
ATE355827T1 (de) 1998-08-12 2007-03-15 Yissum Res Dev Co Mittels ammoniumsulfatgradient hergestellte liposomale therapeutische zusammensetzungen
US6809186B1 (en) 1999-01-22 2004-10-26 Martek Biosciences Corporation Simple method for labeled conjugate production
CA2367590A1 (en) 1999-03-31 2000-10-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
US20030092091A1 (en) * 2000-03-07 2003-05-15 Abrahamson Julie A. Sialoadhesin factor-2 antibodies
AU3069302A (en) 2000-12-13 2002-06-24 Immunex Corp Method for generating immortal dendritic cell lines
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
EP1358910A1 (de) * 2002-05-02 2003-11-05 B.R.A.H.M.S Aktiengesellschaft Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen
AU2003288467A1 (en) 2002-12-13 2004-07-09 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US20050060771A1 (en) 2003-09-11 2005-03-17 Farmer Andrew Alan siRNA encoding constructs and methods for using the same
WO2005051315A2 (en) 2003-11-24 2005-06-09 The Regents Of The University Of California On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
EP1722762A2 (en) * 2004-03-02 2006-11-22 Massachusetts Institute of Technology Nanocell drug delivery system
AU2006232920B2 (en) 2005-04-06 2011-09-29 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
AU2006302848C1 (en) 2005-10-19 2012-08-02 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
EP2060257A1 (en) * 2007-11-08 2009-05-20 Nestec S.A. Prevention and treatment of secondary infections following viral infection
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
JP5641598B2 (ja) * 2009-09-29 2014-12-17 雪印メグミルク株式会社 シアリルラクトース素材の分離方法
JP5788653B2 (ja) * 2010-09-10 2015-10-07 靖人 江原 糖鎖修飾ヌクレオチド及びその使用

Also Published As

Publication number Publication date
BR112014015112A8 (pt) 2017-06-13
EP2793904A1 (en) 2014-10-29
IL233207A0 (en) 2014-07-31
US9789130B2 (en) 2017-10-17
KR20140130664A (ko) 2014-11-11
NZ627650A (en) 2016-01-29
ZA201403861B (en) 2015-09-30
AU2012357968A1 (en) 2014-08-14
BR112014015112A2 (pt) 2017-06-13
AU2012357968B2 (en) 2017-10-05
JP2015500854A (ja) 2015-01-08
MX2014007605A (es) 2015-07-06
CN104168903A (zh) 2014-11-26
CN104168903B (zh) 2017-05-31
JP6143781B2 (ja) 2017-06-07
WO2013092509A1 (en) 2013-06-27
CA2858499A1 (en) 2013-06-27
HK1202820A1 (en) 2015-10-09
US20140370052A1 (en) 2014-12-18
EP2606897A1 (en) 2013-06-26

Similar Documents

Publication Publication Date Title
RU2014130022A (ru) Ингибиторы сиалоадгезина для лечения заболеваний, вызванных вирусами, имеющими оболочку
JP2015500854A5 (cg-RX-API-DMAC7.html)
Pardi et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses
TW202229228A (zh) 可離子化脂質及其製造和使用方法
TWI620568B (zh) 用於治療ｂ型肝炎及ｄ型肝炎感染之方法
US20180193270A1 (en) Exosomes for delivery of therapeutic agents
US12472244B2 (en) Immunogenic compositions and uses thereof
JP2020533334A (ja) アポリポタンパク質Ｃ−ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物
Shi et al. Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants
TW202333780A (zh) 冠狀病毒疫苗
CN114464259A (zh) 一种靶向PD-1 mRNA反义脱氧寡核苷酸的筛选方法及应用
CN116917266A (zh) 可离子化脂质及其制造和使用方法
US20140363464A1 (en) Pre- or post-exposure treatment for filovirus or arenavirus infection
Do et al. The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice
US20220288181A1 (en) Antiviral vaccines using spherical nucleic acids
WO2019161294A1 (en) Targeting lipid metabolism and free fatty acid (ffa) oxidation to treat diseases mediated by resident memory t cells (trm)
Firmino-Cruz et al. Intradermal Immunization of SARS-CoV-2 Original Strain Trimeric Spike Protein Associated to CpG and AddaS03 Adjuvants, but Not MPL, Provide Strong Humoral and Cellular Response in Mice. Vaccines 2022, 10, 1305
Chiang et al. Lipid nanoparticle-formulated DNA acts as a potent immune modulator for cancer immunotherapy through interferon signaling pathways
Ranga Therapeutics for the Treatment
Acchioni et al. Fighting HIV-1 Persistence: At the Crossroads of Shoc-K and B-Lock”. Pathogens 2021, 10, 1517
AU2022212276A9 (en) Chimeric adenoviral vectors
WO2017151939A1 (en) Use of pla2g5-deficient suppressive macrophages in suppression of inflammation
Dale et al. Inhibition of Highly Pathogenic Avian H5N1 Influenza Virus Replication by NanoRNA Oligonucleotides

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20191018